Tenogesic indications
Oral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: 20 mg as a single dose, taken at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest possible duration.
Parenteral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: Initially, 20 mg IM/IV as a single dose given for 1-2 days, to be continued w/ the oral form, administered at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest duration.
Reconstitution: Dissolve lyophilisate in 2 mL of sterile water for inj.
Uses of Tenogesic in details
Tenogesic is used to reduce pain and inflammation (swelling) of the muscles, tendons, and joints in diseases like arthritis or in short-term injuries, strains, or sprains.
Tenogesic description
Novo-Tenogesic, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Tenogesic dosage
Oral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: 20 mg as a single dose, taken at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest possible duration.
Parenteral
Acute musculoskeletal disorders; Osteoarthritis; Rheumatoid arthritis
Adult: Initially, 20 mg IM/IV as a single dose given for 1-2 days, to be continued w/ the oral form, administered at the same time each day. Treatment duration: Up to 7 days for acute musculoskeletal disorders and up to 14 days for severe cases.
Elderly: Use the lowest effective dose for the shortest duration.
Reconstitution: Dissolve lyophilisate in 2 mL of sterile water for inj.
Tenogesic interactions
FELDENE is highly protein bound, and therefore, might be expected to displace other protein-bound drugs. Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels.
Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
Tenogesic side effects
Cardiovascular
Edema; weight gain; CHF; alterations in BP; vasodilation; palpitations; tachycardia.
CNS
Headache; malaise; dizziness; somnolence; vertigo; depression; insomnia; nervousness.
Dermatologic
Pruritus; rash; sweating; erythema; bruising; desquamation; erythema multiforme; toxic epidermal necrolysis.
EENT
Tinnitus; swollen eyes; blurred vision; eye irritation; rhinitis; pharyngitis.
GI
Epigastric distress; nausea; vomiting; anorexia; constipation; stomatitis; abdominal discomfort; diarrhea; flatulence; abdominal pain; indigestion; toxicity (bleeding, ulceration, perforation); heartburn; dyspepsia; anorexia.
Genitourinary
Hematuria; proteinuria; increased BUN and serum creatinine; acute renal insufficiency and failure; papillary necrosis; interstitial nephritis; nephrotic syndrome; hyperkalemia; hyponatremia.
Hematologic
Increased bleeding time; decreased Hgb and Hct; anemia; leukopenia; eosinophilia, thrombocytopenia.
Hepatic
Increased LFTs; elevated liver enzymes.
Respiratory
Bronchospasm; laryngeal edema; dyspnea; hemoptysis; shortness of breath.
Tenogesic contraindications
Hypersensitivity to Tenogesic, aspirin or other NSAIDs. History of or active peptic ulceration, GI bleeding (melaena, haematemesis) or severe gastritis; severe heart failure. Last trimester of pregnancy.
Active ingredient matches for Tenogesic:
Tenoxicam in Thailand.
| Unit description / dosage (Manufacturer) | Price, USD |
| Tenogesic 20 mg x 10 x 10's | |
List of Tenogesic substitutes (brand and generic names): | |
| Tenocam (South Korea, Thailand) | |
| Tenocam 20 mg x 250's (Eurofarma) | |
| Tenoksan (Turkey) | |
| Tenoktil (Turkey, Yemen) | |
| Tenoliof (Georgia) | |
| Tenorix (Bangladesh) | |
| Tenostad (Vietnam) | |
| Tenostad 20 mg x 1 Bottle in 1 tube dung mobi | |
| Tenotec (Brazil) | |
| Tenotil (Vietnam) | |
| Tenotil 20 mg x 10 Tablet | |
| Tenotil 20 mg x 30 Tablet | |
| Tenotil 20 mg x 50 Tablet | |
| Tenotil 20 mg x 100 Tablet | |
| Tenotil 20 mg x 500 Tablet | |
| Tenotil 20 mg x 1000 Tablet | |
| Tenox (Bosnia & Herzegowina, Bulgaria, Croatia (Hrvatska), Finland, Georgia, Hungary, Ireland, Latvia, Lithuania, Poland, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Thailand, Turkey) | |
| Tablet; Oral; Amlodipine Maleate 10 mg (KRKA) | |
| Tablet; Oral; Amlodipine Maleate 5 mg (KRKA) | |
| Tenox 5mg - 30 Tablets (KRKA) | $ 22.70 |
| Tenox 10mg - 30 Tablets (KRKA) | $ 25.00 |
| Tenox 20 mg x 20 x 10's (KRKA) | |
| Tenox tab 10 mg 30's (KRKA) | |
| Tenox tab 5 mg 30's (KRKA) | |
| Tenoxam (Yemen) | |
| Tenoxen (Brazil) | |
| Tenoxicam (Belgium, Bulgaria, Denmark, France, Iceland, Italy, Japan, Lithuania, Luxembourg, New Zealand, Romania, Switzerland, Turkey) | |
| Tablet; Oral; Tenoxicam 20 mg (Arena group) | |
| Capsule; Oral; Tenoxicam 20 mg (Arena group) | |
| Apo-Tenoxicam 20 mg Tablet (Arena group) | $ 1.21 |
| Ténoxicam | |
| Tablet; Oral; Tenoxicam 20 mg | |
| Capsule; Oral; Tenoxicam 20 mg | |
| Apo-Tenoxicam 20 mg Tablet | $ 1.21 |
| Tablet; Oral; Tenoxicam 20 mg | |
| Capsule; Oral; Tenoxicam 20 mg | |
| Apo-Tenoxicam 20 mg Tablet | $ 1.21 |
| Tenoxicam 20 | |
| Tenoxicam AA Pharma (Canada) | |
| Tenoxicam AFT (New Zealand) | |
| Tenoxicam Alternova (Denmark) | |
| Tenoxicam American Generics (Colombia) | |
| Tenoxicam Arena (Romania) | |
| Tenoxicam Bidiphar (Vietnam) | |
| Tenoxicam Bidiphar 20 mg x 3 Blister x 10 Tablet | |
| Tenoxicam Bidiphar 20 mg/2 mL x 1 Bottle in 1 tube dung mobi 2 mL | |
| Tenoxicam el obour (Egypt) | |
| Tenoxicam EMS (Brazil) | |
| Tenoxicam Etyc (Colombia) | |
See 243 substitutes for Tenogesic | |
References
- PubChem. "tenoxicam". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "tenoxicam". http://www.drugbank.ca/drugs/DB00469 (accessed September 17, 2018).
- DTP/NCI. "tenoxicam: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Tenogesic are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tenogesic. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yet2 consumers reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?The below mentioned numbers have been reported by ndrugs.com website users about whether the Tenogesic drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
| Users | % | ||
|---|---|---|---|
| Not expensive | 1 | 50.0% | |
| Expensive | 1 | 50.0% | |
Consumer reported time for results
No survey data has been collected yet5 consumers reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 3 | 60.0% | |
| 16-29 | 1 | 20.0% | |
| 6-15 | 1 | 20.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
